Novo Nordisk increased its operating profit by nearly a third last year.
Sales of Victoza, NovoRapid and Levemir resulted in an operating profit increase of 27% and a net profit rise of 34%.
Lars Rebien Sørensen, President and CEO, described 2010 as a “very good year” for the Danish company.
Novo Nordisk also reached its four long-term financial targets in 2010 as announced in their annual report for 2008.
Sales of modern insulins increased by 24%, as did sales in international operations. For 2011, Novo Nordisk now calculates sales growth measured in local currencies to be between 8% and 10%, and operating profit growth measured in local currencies is expected to be around 15%.
“We expect continued sales growth from these products and are encouraged by the results from the phase 3 programme with our new generation insulins,” said Mr Sørensen.
Share this article: